Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sopharma Trading ADXBUL:SFT 82 PE Ratio without NRI is 3.90 as of Jul. 17, 2026, which is 87% below its 10-year median of 29.09. GuruFocus rates XBUL:SFT with a GF Score™ of 82/100 and a GF Value™ of €7.67 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 87 Medical Distribution companies, Sopharma Trading AD ranks better than 97.7% on this metric.
The PE Ratio without NRI, or P/E Ratio without non-recurring items, is a financial ratio used to compare a company's market price to its EPS without NRI. As of today (2026-07-17), Sopharma Trading AD's share price is €2.86.
Sopharma Trading AD's EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 was €0.73. Therefore, Sopharma Trading AD's PE Ratio without NRI for today is 3.90.
During the past 13 years, Sopharma Trading AD's highest PE Ratio without NRI was 113.13. The lowest was 3.64. And the median was 29.09.
Sopharma Trading AD's EPS (Basic) for the
three
months ended in Mar. 2026 was €0.24.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 was €0.76.
Sopharma Trading AD (XBUL:SFT) PE Ratio without NRI Explanation
The PE Ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.
In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio is positive. Also for stocks with the same PE Ratio, the one with faster growth business is more attractive.
If a company loses money, the PE Ratio becomes meaningless.
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio divided by the growth ratio. He thinks a company with a PE Ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio of 20, instead of a company growing 10% a year with a PE Ratio of 10.
Because the PE Ratio measures how long it takes to earn back the price you pay, the PE Ratio can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.
Investors need to be aware that the PE Ratio can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratio s are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio.
Sopharma Trading AD PE Ratio without NRI Related Terms
Sopharma Trading AD PE Ratio without NRI Historical Data
* Premium members only.
The historical data trend for Sopharma Trading AD's PE Ratio without NRI can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XBUL:SFT vs MCK, CAH, COR: PE Ratio without NRI Comparison
For the Medical Distribution subindustry, Sopharma Trading AD's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sopharma Trading AD PE Ratio without NRI vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Sopharma Trading AD's PE Ratio without NRI distribution charts can be found below:
* The bar in red indicates where Sopharma Trading AD's PE Ratio without NRI falls into.
Sopharma Trading AD PE Ratio without NRI Calculation
The PE Ratio without NRI, or P/E Ratio without non-recurring items, is a financial ratio used to compare a company's market price to its EPS without NRI. Regular PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than regular PE Ratio.
Sopharma Trading AD's Share Price of today is €2.86.
Sopharma Trading AD's EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.73.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
There are at least three kinds of PE Ratios used by different investors. They are Trailing Twelve Month PE Ratio, Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio based on inflation-adjusted normalized PE Ratio is called Shiller PE Ratio, after Yale professor Robert Shiller.
In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.
In the calculation of PE Ratio (TTM), the earnings per share used are the earnings per share over the past 12 months.
For Forward PE Ratio, the earnings are the expected earnings for the next twelve months.
For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.
Sopharma Trading AD (XBUL:SFT) has a PE Ratio without NRI of 3.90 as of Jul. 17, 2026. P/E without nonrecurring items is the ratio of share price to a company's earnings less one-time charges. View historical data on Sopharma Trading AD and its competitors. This is 87% below median its historical median of 29.09. Over the past decade, Sopharma Trading AD's PE Ratio without NRI has ranged from 3.64 to 113.13. According to the industry distribution chart, Sopharma Trading AD ranks #2 out of 87 companies in the Medical Distribution industry, placing it in the top 2.3%.
Is Sopharma Trading AD's PE Ratio without NRI too high?
Sopharma Trading AD's current PE Ratio without NRI of 3.90 is 87% below median its 10-year median of 29.09. Over the past 10 years, this metric has ranged from a low of 3.64 to a high of 113.13. The Medical Distribution industry median PE Ratio without NRI is 14.96. Sopharma Trading AD's value of 3.90 is 73.9% below this industry median. Based on the distribution chart, Sopharma Trading AD ranks #2 out of 87 companies in the Medical Distribution industry, which is in the top quartile — a strong position relative to peers. Overall, Sopharma Trading AD has a GF Score™ of 82/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sopharma Trading AD's PE Ratio without NRI compare to MCK and CAH?
According to the Medical Distribution industry distribution chart, Sopharma Trading AD ranks #2 out of 87 companies for PE Ratio without NRI. This places Sopharma Trading AD in the top 2% of its industry — outperforming the majority of peers. The industry median PE Ratio without NRI is 14.96. Sopharma Trading AD's value of 3.90 is 73.9% below this benchmark. Historically, Sopharma Trading AD's own PE Ratio without NRI has ranged from 3.64 to 113.13 over the past decade. While the company's 10-year median is 29.09 vs. the industry median of 14.96, Sopharma Trading AD has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PE Ratio without NRI for a Medical Distribution company?
The median PE Ratio without NRI among Medical Distribution companies is 14.96, based on 87 companies in the industry. Companies in the top quartile (top 25%) have a PE Ratio without NRI significantly above this median, while those in the bottom quartile fall well below. However, PE Ratio without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sopharma Trading AD's current PE Ratio without NRI of 3.90 is 73.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PE Ratio without NRI mean?
A high PE Ratio without NRI can signal that a stock is expensive relative to its fundamentals. P/E without nonrecurring items is the ratio of share price to a company's earnings less one-time charges. View historical data on Sopharma Trading AD and its competitors. For the Medical Distribution industry, the median PE Ratio without NRI is 14.96 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sopharma Trading AD's current PE Ratio without NRI is 3.90, which is 87% below median its own 10-year median of 29.09. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sopharma Trading AD stock overvalued right now?
Based on GuruFocus' analysis, Sopharma Trading AD (XBUL:SFT) is currently considered Significantly Undervalued. The stock's GF Value™ is €7.67, compared to a current price of €2.86 — trading 62.7% below its estimated fair value. The current PE Ratio without NRI is 3.90, which is 87% below median its 10-year median of 29.09 and 73.9% below the Medical Distribution industry median of 14.96. Sopharma Trading AD's overall GF Score™ is 82/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PE Ratio without NRI calculated?
PE Ratio without NRI is calculated from a company's financial statements. For Sopharma Trading AD (XBUL:SFT), the current PE Ratio without NRI is 3.90 as of Jul. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sopharma Trading AD (XBUL:SFT) Overvalued in 2026?
Based on GuruFocus' analysis, Sopharma Trading AD stock appears to be undervalued.
The current stock price of €2.86 is trading 62.7% below its estimated GF Value™ of €7.67.
GuruFocus considers Sopharma Trading AD to be Significantly Undervalued.
Key valuation signals for XBUL:SFT:
PE Ratio without NRI: 3.90 (87% below median its 10-year median of 29.09)
GF Value™: €7.67 vs. price of €2.86 (62.7% below fair value)
Industry Position: 73.9% below the Medical Distribution median (#2 of 87)
No single metric tells the full story. See the XBUL:SFT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sopharma Trading AD is a Bulgaria based company operating in the pharmaceutical sector. The company is engaged in the distribution of pharmaceutical items, including a portfolio of international brands, medicinal products, medical supplies, sanitary and hygienic materials, vitamins, nutritional supplements, cosmetics, medical equipment, and equipment. It also provides turnkey solutions for the construction of medical and hospital establishments. In addition, the group also caters logistics solutions for import, storage, and distribution of goods to end customers.
82GF Score
Get the complete analysis for XBUL:SFT
PE Ratio without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XBUL:SFT has been successfully added to your 
